

Best-value biological (BVB) medicines / Best-value medicines (BVM) 2023

The HSE-Medicines Management Programme has identified the following biological medicines for which it may conduct a best-value biological (BVB) medicine or best-value medicine (BVM) process in 2023:

- Adalimumab (L04AB04)
- Eculizumab (L04AA25)
- Etanercept (L04AB01)
- Filgrastim (L03AA02)
- Follitropin alfa (G03GA05)
- Lipegfilgrastim (L03AA14)
- Liraglutide (A10BJ02)
- Natalizumab (L04AA23)
- Pegfilgrastim (L03AA13)
- Teriparatide (H05AA02)
- Tocilizumab (L04AC07)